Radiobromination of monoclonal antibody using potassium [76Br] (4 isothiocyanatobenzyl-ammonio)-bromo-decahydro-closo-dodecaborate (Bromo-DABI)

被引:36
作者
Bruskin, A
Sivaev, I
Persson, M
Lundqvist, H
Carlsson, J
Sjöberg, S
Tolmachev, V [1 ]
机构
[1] Uppsala Univ, Rudbecklab, Unit Biomed Radiat Sci, S-75185 Uppsala, Sweden
[2] Uppsala Univ, Dept Organ Chem, Uppsala, Sweden
[3] Russian Acad Sci, AN Nesmeyanov Organoelement Cpds Inst, Moscow, Russia
关键词
indirect radiobromination; monoclonal antibody; (4 isothiocyanatobenzyl-ammonio)-bromo-decahydro-closo-dodecaborate;
D O I
10.1016/j.nucmedbio.2003.08.005
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The use of charged linkers in attaching radiohalogens to tumor-seeking biomolecules may improve intracellular retention of the radioactive label after internalization and degradation of targeting proteins. Derivatives of polyhedral boron clusters, such as closo-dodecaborate (2-) anion. might be possible charged linkers. In this study, a bifunctional derivative of closo-dodecaborate, (4-isothiocyanatobenzyl-ammonio)-undecahydro-closo-dodecaborate (DABI) was labeled with positron-emitting nuclide Br-76 (T 1/2 = 16.2 h) and coupled to anti-HER2/neu humanized antibody Trastuzumab. The overall labeling yield at optimized conditions was 80.7 +/- 0.6%. The label was proven to be stable in vitro in physiological and a set of denaturing conditions. The labeled antibody retained its capacity to bind to HER-2/neu antigen expressing cells. The results of the study demonstrated feasibility for using derivatives of closo-dodecaborate in indirect labeling of antibodies for radioimmunoPET. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:205 / 211
页数:7
相关论文
共 42 条
[1]   Increased level of c-erbB-2/neu/HER-2 protein in cutaneous squamous cell carcinoma [J].
Ahmed, NU ;
Ueda, M ;
Ichihashi, M .
BRITISH JOURNAL OF DERMATOLOGY, 1997, 136 (06) :908-912
[2]   Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations [J].
Behr, TM ;
Goldenberg, DM ;
Becker, W .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1998, 25 (02) :201-212
[3]  
Browne E., 1986, Table of Radioactive Isotopes
[4]   Perceptions of Herceptin®:: A monoclonal antibody for the treatment of breast cancer [J].
Dillman, RO .
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1999, 14 (01) :5-10
[5]  
Foulon CF, 2000, CANCER RES, V60, P4453
[6]   Positively charged templates for labeling internalizing antibodies:: comparison of N-succinimidyl 5-Iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR [J].
Foulon, CF ;
Welsh, PC ;
Bigner, DD ;
Zalutsky, MR .
NUCLEAR MEDICINE AND BIOLOGY, 2001, 28 (07) :769-777
[7]  
GEISSLER F, 1992, CANCER RES, V52, P2907
[8]   Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer [J].
Goldenberg, MM .
CLINICAL THERAPEUTICS, 1999, 21 (02) :309-318
[9]   Optimized indirect 76Br-bromination of antibodies using N-succinimidyl para-[76Br]bromobenzoate for radioimmuno PET [J].
Höglund, J ;
Tolmachev, V ;
Orlova, A ;
Lundqvist, H ;
Sundin, A .
NUCLEAR MEDICINE AND BIOLOGY, 2000, 27 (08) :837-843
[10]  
HOGLUND J, 2001, J LABEL COMP RADI S1, V44, P712